~~<i id='DE51CF8B3B'><strike id='DE51CF8B3B'><tt id='DE51CF8B3B'><pre id='DE51CF8B3B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：hotspot 2025-09-09 19:27:46 - browse：392

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： ACIP vaccine advisory panel sees its vacancies filled

explore

leisure time

focus

hotspot

Sen.BernieSanders(I-Vt.)raiseshishandataThursdayhearingonCapitolHillinWashingtontoexaminethecostofpr

WSS

Congress might make insulin pumps more accessible to the blind

Snowpack in the West is melting rapidly. Where will all that extra water go?

Doctors increasingly discourage vaping amid mounting health concerns

Long Covid research funding gets a major boost from NIH

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Latigo launches with $135 million for Vertex

hotspot

explore

explore

At least 13 dead in Texas as scorching temps continue

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

Anesthesiologist group: stop taking Ozempic before surgery

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

New air purifier tech could be key to improving indoor air quality

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Apple is now the first public company to be valued at $3 trillion

Here’s what’s in the FDA plan to include pregnant women in clinical trials

How to save PrEP access — and even expand it

Report cites 'urgent' need to recruit more diverse clinical trial participants

leisure time

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Readout Newsletter: Amylyx, Aurinia, and IQVIA

AMAs digital advisors table RPM coding reform proposal, again

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

'Weather

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

leisure time

focus

hotspot

hotspot